Cell Expansion Market Size & Growth Forecast 2027–2036, By Segments (Product, End-use, Cell Type, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Cell Expansion Market size was more than USD 28.7 billion in 2026 and is set to grow at a 12.45% CAGR between 2027 and 2036, surpassing USD 92.78 billion by 2036. The industry revenue for 2027 is estimated at USD 31.71 billion.

• Base Year Value (2026): USD 28.7 billion
• CAGR (2027-2036): 12.45%
• Forecast Year Value (2036): USD 92.78 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Cell Expansion Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held 41.34% share, supported by strong biopharmaceutical companies, advanced cell therapy research, established manufacturing infrastructure, and CRO/CDMO networks enabling efficient cell processing.
  • Asia Pacific is projected at 14.34% CAGR, driven by expanding biotechnology base, rising cell therapy investment, growing research institutions, and increasing scale-up capacity for expansion technologies.

• Segment Momentum:

  • Consumables captured 48.44% of the market in 2026 because cell expansion workflows require continuous replenishment of media, reagents, sera, and other single-use materials across research and production activities.
  • Research Institutes are the fastest-growing end-use segment as more programs in stem cells, immunology, and disease modeling incorporate scalable cell expansion into routine laboratory and translational research workflows.

• Market Expansion Drivers:

  • Increasing adoption of automated cell expansion systems improving biologics and cell therapy manufacturing efficiency.
  • Growing demand for single-use systems reducing contamination risks in cell therapy production workflows.
  • Rising investments in stem cell and gene therapy research accelerating scalable cell expansion platform development.

• Leading Market Participants:

  Leading companies in the cell expansion market include Thermo Fisher Scientific Inc. (United States), Cytiva (United States), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (United States), STEMCELL Technologies Inc. (Canada), Miltenyi Biotec B.V. & Co. KG (Germany), Becton, Dickinson and Company (United States), Terumo Blood and Cell Technologies, Inc. (United States), Takara Bio Inc. (Japan).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 28.7 billion
  • 2027 Estimated Market Size: USD 31.71 billion.
  • Projected Market Size: USD 92.78 billion by 2036
  • Growth Forecasts: 12.45% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Consumables (Product) | Biopharmaceutical & Biotechnology Companies (End-use) | Mammalian (Cell Type) | Biopharmaceuticals (Application)
  • Emerging Opportunity Segment: Instruments (Product) | Research Institutes (End-use) | Mammalian (Cell Type) | Vaccine Production (Application)

Market Growth Drivers and Industry Trends

Increasing adoption of automated cell expansion systems improving biologics and cell therapy manufacturing efficiency

Automation is becoming increasingly important in cell-based manufacturing, as the cell expansion market benefits from technologies that improve process consistency, scalability, and operational control. Automated systems can reduce manual handling requirements, standardize critical expansion steps, and support reproducible cell growth across development and manufacturing environments. Their integration into biologics and cell therapy workflows also enables manufacturers to manage complex processes with greater efficiency while reducing operator-dependent variability, particularly where production requires controlled and repeatable expansion of viable cells.

Growing demand for single-use systems reducing contamination risks in cell therapy production workflows

The growing emphasis on process safety and contamination control is encouraging manufacturers to adopt disposable components and closed processing approaches, supporting the cell expansion market across cell therapy production. Single-use systems can limit exposure to external contaminants by reducing the need for repeated cleaning and sterilization of processing equipment, while also simplifying changeover between manufacturing batches. These advantages are particularly relevant to sensitive cell-based workflows where maintaining cell viability and product integrity is critical, encouraging wider incorporation of single-use bioreactors, vessels, tubing, and related expansion equipment.

Rising investments in stem cell and gene therapy research accelerating scalable cell expansion platform development

Increasing investment in stem cell and gene therapy research is creating a stronger need for technologies capable of producing sufficient quantities of high-quality cells for research, clinical development, and manufacturing applications. The cell expansion market will be propelled by efforts to develop scalable platforms that can support cell proliferation while maintaining viability and desired cellular characteristics. As therapies progress from laboratory research toward larger-scale development, researchers and manufacturers require expansion systems that can accommodate increasing production requirements, standardized processes, and controlled culture conditions for complex cell-based applications.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing adoption of automated cell expansion systems improving biologics and cell therapy manufacturing efficiency	2.00%	High	North America, Europe, Asia Pacific	High	Near Term
Growing demand for single-use systems reducing contamination risks in cell therapy production workflows	1.70%	Moderate	North America, Asia Pacific	High	Mid Term
Rising investments in stem cell and gene therapy research accelerating scalable cell expansion platform development	1.50%	High	Europe, North America	Medium	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America dominated the cell expansion market, accounting for a 41.34% share in 2026. The region’s leading position is supported by advanced biotechnology and life sciences infrastructure, strong research capabilities, and widespread adoption of cell-based technologies across biopharmaceutical development and regenerative medicine. Continued investment in cell and gene therapy research is increasing demand for reliable and scalable cell expansion solutions, while sophisticated laboratory facilities and established expertise in bioprocessing are facilitating the integration of advanced expansion technologies into research and production workflows.

Asia Pacific is expected to be the fastest-growing region, driven by expanding biopharmaceutical manufacturing capabilities, increasing research activity, and growing investment in biotechnology infrastructure. Rising demand for advanced therapeutic development is encouraging laboratories and manufacturers to adopt more efficient cell culture and expansion processes. Improvements in healthcare infrastructure, increasing scientific capabilities, and greater emphasis on domestic biotechnology production are also creating favorable conditions for broader adoption of cell expansion technologies.

Key Country Insights

United States

Bioprocess Scale-Up Hub

The U.S. cell expansion market is shaped by high-volume biopharmaceutical manufacturing and increasing demand for advanced cell therapies. U.S.-based developers prioritize scalable expansion platforms, automation integration, and process consistency to support commercial-stage biologics production.

Japan

Regenerative Therapy Alignment

Japan’s cell expansion market is closely tied to regenerative medicine applications, where process reliability and product quality remain critical. Japanese manufacturers are investing in specialized expansion systems to support stem cell therapies and personalized treatment development.

South Korea

Contract Bioproduction Focus

South Korea is strengthening its role in outsourced biologics manufacturing, driving demand for efficient cell expansion technologies. Local priorities center on increasing throughput, reducing contamination risks, and improving production flexibility for diverse therapeutic pipelines.

Germany

Precision Manufacturing Base

Germany emphasizes controlled bioprocessing environments and high-specification equipment for cell expansion workflows. The country’s focus on biomanufacturing quality and reproducibility supports demand for closed-system technologies and optimized cell culture media.

France

Clinical Translation Support

France is aligning cell expansion demand with translational research and hospital-based cell therapy programs. The market in France shows growing interest in flexible systems that can bridge laboratory development with regulated clinical production environments.

Italy

Research-Led Application Base

Italy’s cell expansion market is influenced by academic and early-stage therapeutic research, particularly in oncology and tissue engineering. Italian institutions are focusing on adaptable expansion platforms that support experimental workflows and pilot-scale production.

Segment Leadership and Growth Trends

 

Product Segment Analysis: Consumables (Largest Segment) vs Instruments (Fastest-Growing Segment)

Consumables represented the largest share of the cell expansion market at 48.44% in 2026, reflecting their essential role in maintaining continuous cell expansion workflows. Culture media, vessels, reagents, and related consumable products are repeatedly required across laboratory and production processes, generating recurring demand. The increasing use of cell-based research and biopharmaceutical manufacturing is supporting greater consumption of specialized materials required for reliable and scalable cell expansion.

Instruments are the fastest-growing product segment, driven by increasing demand for automated and controlled cell expansion processes. Advanced instruments can improve process consistency, reduce manual intervention, and support the monitoring and management of cells during expansion. As cell-based applications become more sophisticated and production workflows move toward greater scalability and automation, demand for dedicated expansion instruments is strengthening.

End-use Segment Analysis: Biopharmaceutical & Biotechnology Companies (Largest Segment) vs Research Institutes (Fastest-Growing Segment)

Biopharmaceutical & biotechnology companies held the largest share of the cell expansion market, accounting for 49.08% in 2026, supported by extensive use of cell expansion technologies in biologic development, manufacturing, and advanced cell-based applications. These organizations require reproducible and scalable expansion processes to generate sufficient cell populations for research and production activities. Increasing development of biologics and other cell-dependent applications continues to reinforce demand from this end-use group.

Research institutes are the fastest-growing end-use segment, supported by expanding investigation into cell biology, regenerative medicine, disease modeling, and other cell-based research areas. Research environments require flexible expansion systems capable of supporting diverse experimental workflows and increasingly sophisticated cellular studies. Greater emphasis on understanding cellular behavior and developing new therapeutic approaches is encouraging research institutes to adopt advanced cell expansion technologies.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Consumables, Culture Flasks and Accessories, Instruments	Consumables	Instruments
End-use	Biopharmaceutical & Biotechnology Companies, Research Institutes, Cell Banks, Others	Biopharmaceutical & Biotechnology Companies	Research Institutes
Cell Type	Mammalian, Microbial, Others	Mammalian	Mammalian
Application	Biopharmaceuticals, Tissue Culture & Engineering, Vaccine Production, Drug Development, Gene Therapy, Cancer Research, Stem Cell Research, Others	Biopharmaceuticals	Vaccine Production

Competitive Landscape and Market Positioning

Major players in the cell expansion market:

1. Thermo Fisher Scientific Inc. (United States)

2. Cytiva (United States)

3. Merck KGaA (Germany)

4. Sartorius AG (Germany)

5. Corning Incorporated (United States)

6. STEMCELL Technologies Inc. (Canada)

7. Miltenyi Biotec B.V. & Co. KG (Germany)

8. Becton Dickinson and Company (United States)

9. Terumo Blood and Cell Technologies Inc. (United States)

10. Takara Bio Inc. (Japan)

The cell expansion market is advancing through increasing adoption of regenerative medicine and cell-based therapies across healthcare applications. Manufacturers are developing scalable expansion systems, automated bioprocessing platforms, and optimized culture technologies to improve cell yield and consistency. Growing investment in advanced therapeutics is also driving innovation in the cell expansion market.

Industry Development/News

Company Name	Date	Key Development
PL BioScience	Jul-25	PL BioScience inaugurated a 1,200-square-meter facility in Germany to increase the production capacity of Human Platelet Lysate. This strategic infrastructure expansion is intended to address the growing demand for high-quality cell culture supplements, thereby bolstering the company’s commercial manufacturing capabilities for cell expansion and broader regenerative medicine applications.
MaxCyte	Jun-25	MaxCyte entered a strategic collaboration with Ori Biotech to evaluate manufacturing workflows for autologous cell therapies. By utilizing CD19 CAR expression as a test system, the initiative seeks to optimize scalable cell engineering and expansion processes, aiming to enhance manufacturing efficiency and throughput for next-generation CAR-T and autologous therapeutic platforms.
FUJIFILM Irvine Scientific	Jan-25	FUJIFILM Irvine Scientific partnered with Terumo Blood and Cell Technologies to integrate its PRIME-XV T Cell Expansion Media with the Quantum Flex Cell Expansion System. This collaboration is designed to enhance the consistency, reliability, and scalability of T-cell manufacturing processes, supporting more efficient and reproducible production of advanced cellular therapies.
Cytiva	Jun-24	Cytiva introduced the Sefia next-generation cell therapy manufacturing platform to streamline the production of CAR-T and other cell-based therapies. The platform is engineered to improve cell processing efficiency and reduce overall manufacturing costs, providing a scalable solution for developers aiming to accelerate the commercialization of sophisticated cell expansion workflows.
Evotec	Apr-24	Just-Evotec Biologics, a subsidiary of Evotec, announced a significant investment in a new facility to expand its continuous biomanufacturing capacity. This project focuses on scaling automated, advanced cell-based manufacturing technologies, reinforcing the company’s strategic commitment to high-capacity production infrastructure necessary for the development of next-generation cell and biologic therapeutics.
panCELLa	May-23	panCELLa entered into a research agreement with BioCentriq to evaluate stem cell-derived Natural Killer (NK) cell expansion technology. By leveraging panCELLa’s genetically engineered feeder cells, the collaboration aims to improve the expansion rate, total yield, and potency of manufactured NK cells, representing a targeted approach to enhancing technical capabilities in cell therapy production.